Table 1.
Demographic and disease specific features of the group and relationship between perceived stress are presented.
| PSS | ||||
|---|---|---|---|---|
| N (%) | Mean±SD1 (min-max) | p or r and p-value | ||
| Gender | Male | 53 (25.9%) | 0.1a | |
| Female | 152 (74.1%) | |||
| Age (years) | 37.7 ± 10.0 (15-71) | -0.08, 0.2b | ||
| Marital status | Married | 139 (67.8%) | 0.7c | |
| Single | 43 (21.0%) | |||
| Widowed | 23 (11.2%) | |||
| Educational status | Primary school graduates | 41 (20%) | 0.1c | |
| Secondary school graduates | 29 (14.1%) | |||
| High school graduates | 51 (24.9%) | |||
| University graduates | 84 (41.0%) | |||
| Employment status | Employed | 97 (47.3%) | 0.9a | |
| Unemployed | 108 (52.7%) | |||
| Income level | Good | 51 (24.9%) | 0.07c | |
| Moderate | 137 (66.8%) | |||
| Poor | 17 (8.3%) | |||
| Age at diagnosis (years) | 30.0 ± 9.1 (12-69) | -0.006, 0.9b | ||
| MS type | RRMS2 | 189 (92.2%) | ||
| SPMS3 | 12 (5.9%) | |||
| PPMS4 | 4 (2%) | |||
| Disease duration (years) | 7.4 ± 6.5 (1-34) | -0.007, 0.9b | ||
| EDSS | 2.1 ± 1.4 (0-6.5) | -0.03, 0.5b | ||
| DMT5 | Oral Injectabl Intravenous |
101 (49.3%) 65 (31.7%) 30 (14.6%) |
||
| Relapse in first six months of the pandemic | Yes No |
17 (8.3%) 188 (91.7%) |
0.6a |
1
Standard deviation.
2
Relapsing remitting multiple sclerosis.
3
Secondary progressive multiple sclerosis.
4
Primary progressive multiple sclerosis.
5
Disease modifying therapy.
a
Mann Whitney U test.
b
Spearman correlation.
c
Kruskal Wallis test.